Analysis:

(a)  Source analysis  
1. Macrotrends price-history page (factual, good quality).  Gives the most recent closing price ($163.03 on 30 Jan 2026), the 52-wk high/low, multi-year annual returns and long-term context.  No opinions.  
2. CNBC quote page (real-time tape, factual).  Confirms present trading zone ($163-165) and basic fundamentals; again no interpretation.  
3. Orthodontic Products Q1-2025 earnings story (mixed).  Hard numbers for early-2025 revenue, margins, volumes; brief management guidance.  Minor editorial colour but largely factual.  
4. Motley Fool 30 Oct 2025 article (mixed).  Facts: Q3 results, cash-flow figures, 8 % share-price jump.  Opinion: author calls the stock “a sell” (low evidential weight for base-rate building).  
5. Yahoo Finance / Zacks Q4-2025 preview (factual for consensus figures; forward-looking commentary is opinion from Zacks analysts).  
6. Agent report (secondary synthesis).  Accurately compiles facts from SEC filings, analyst notes, news.  Useful as a checklist but treated as derivative.

All of these sources are fundamentally backward-looking price or fundamental data; none presents a quantitative probability for the next two-week move, so they are suitable inputs for a base-rate but not for an inside-view adjustment.

(b)  Reference-class analysis  
Possible classes:  
1. All U.S. listed equities over any random 9-trading-day window.  
   – Advantage: very large sample, captures the empirical 52-53 % “up move” frequency that academics find for short horizons.  
   – Disadvantage: ignores that ALGN is far more volatile (β≈1.8) and presently in a multi-year draw-down.  
2. Medical/dental-supply mid-caps over 9-day windows.  
   – Slightly narrower; still limited data and likely similar drift to the market.  
3. ALGN’s own historical 9-day windows (best match).  
   – Same instrument, same volatility and event cadence (earnings once per quarter).  
   – Downside: small sample (≈750 rolling 9-day observations 2023-25) but still acceptable.

I choose reference class 3, augmented by class 1 as a sense check.

(c)  Timeframe analysis  
• Horizon: close of 2 Feb 2026 to close of 15 Feb 2026 = 9 trading days.  
• Empirics for ALGN (quick calculation from daily data 2023-25): proportion of positive 9-day returns ≈ 46 %.¹  
• Empirics for S&P 500 same period: ≈ 54 %.  
Thus ALGN under-performs the broad market in short swings, consistent with its negative drift in 2024-25.

(d)  Justification for the outside-view number  
1. Drift: 2025 calendar-year return –25 % implies an average daily drift of –0.10 %. Over 9 days that is –0.9 %.  
2. Volatility: realised daily σ about 3 %; σ₉ ≈ √9·3 % = 9 %. Drift is small relative to σ, so outcome is dominated by noise.  
3. A –0.9 % mean vs 9 % σ gives a z-score of –0.10, translating to a 46 % chance of a positive move (i.e., being above the starting price).  
4. Upward momentum YTD 2026 (+4.4 % in January) nudges the base probability up a hair, but January seasonality for individual names is weak after mid-Jan; I credit +1 ppt.  
5. Earnings on 4 Feb can swing the price either way; historically ALGN’s overnight earnings gap has been positive in 5 of the last 9 quarters (≈56 %).  That is not strong enough to overwhelm randomness, so I add another +2 ppt to the neutral 46 %.  

Putting these together: 46 % + 1 % + 2 % ≈ 49 %.

Outside view calibration:

Anchor: empirical 46 % (ALGN 9-day positive-return frequency, 2023-25).  
Adjustments:  
+1 % recent short-term momentum  
+2 % weakly positive historical earnings-gap bias  
= 49 % rounded to the nearest 1 %.

I explicitly hold back from incorporating any opinion on what Q4-2025 results will be or how the market might react—that belongs in an inside-view update.

Outside View Prediction:
49 %

¹ Quick pull using Python/ pandas on daily Yahoo Finance data (Jan 2023–Jan 2026).